Maternal Vaccine and Infant RSV Shot Prove Comparable

A new study shows both interventions effectively reduce severe RSV outcomes for infants during their first months of life.

Updated on Oct. 28, 2026 in Babies

Maternal Vaccine and Infant RSV Shot Prove Comparable

Live Poll

Do you prefer relying on your own research to choose medical preventions for your newborn?

Research published in JAMA Network Open finds no statistically significant difference in protection against RSV between maternal vaccination and infant antibody shots. Both methods show high efficacy in preventing infections and hospitalizations in full-term infants.

Why it matters

The findings provide essential information for parents and pediatricians navigating preventative options for respiratory syncytial virus. Understanding the comparative effectiveness of these two primary immunization strategies helps guide healthcare decision-making during the RSV season.

The study analyzed 15,124 infants, recording infection rates of 0.94% for the maternal vaccine group and 1.04% for the nirsevimab group. Maternal vaccination is administered at 32 to 36 weeks of pregnancy, while nirsevimab is given in the first week of life.

The players

JAMA Network Open

This is a peer-reviewed, open-access medical journal published by the American Medical Association that features research across all health disciplines.

National Institute of Allergy and Infectious Diseases

This federal agency conducts and supports research to better understand, treat, and ultimately prevent infectious and allergic diseases.

Kaiser Permanente Division of Research

This organization conducts health research to improve patient care and healthcare delivery within its integrated healthcare system.

The details

Researchers matched infants by birth week, sex, and various maternal demographic factors to analyze outcomes between 8 and 180 days of age. The study, which also documented 12 total hospitalizations, was supported by the National Institute of Allergy and Infectious Diseases and the Kaiser Permanente Division of Research.

The study followed infants through the 2023-24 RSV season.
Data collection continued throughout the 2024-25 RSV season.
Results were published and presented at IDWeek on October 24, 2026.

Culture Shift

This study follows a pattern of presenting clinical effectiveness data at the IDWeek scientific conference to inform national healthcare practices. It marks a significant milestone in pediatric immunology, providing evidence that shifts focus toward individualized choice between two proven protective products.

Parents can consult with pediatricians to determine which RSV prevention method best fits their pregnancy timeline or newborn's first days of life. Both the maternal vaccine and nirsevimab are proven to significantly reduce the risk of hospitalization compared to having no protection.

The takeaway

Both available RSV interventions show high effectiveness in reducing infections and preventing severe outcomes for newborns. Families should discuss these options during prenatal and postnatal care to ensure the most appropriate protection for their child.